Gujarat Themis Biosyn Limited (BOM:506879)

Market Cap	43.42B +26.0%
Revenue (ttm)	1.59B +2.7%
Net Income	477.89M -9.2%
EPS	4.39 -9.1%
Shares Out	108.97M
PE Ratio	90.85
Forward PE	n/a
Dividend	0.67 (0.17%)
Ex-Dividend Date	Sep 4, 2025

Volume	9,858
Average Volume	26,496
Open	399.50
Previous Close	398.50
Day's Range	390.15 - 412.00
52-Week Range	225.75 - 479.45
Beta	0.31
RSI	73.32
Earnings Date	Feb 5, 2026

About Gujarat Themis Biosyn

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1981
• Employees: 221
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 506879

Financial Performance

In fiscal year 2025, Gujarat Themis Biosyn's revenue was 1.51 billion, a decrease of -11.20% compared to the previous year's 1.70 billion. Earnings were 487.72 million, a decrease of -17.56%.